

Anna K Blakney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5178168/publications.pdf>

Version: 2024-02-01

47
papers

2,709
citations

201385

27
h-index

233125

45
g-index

53
all docs

53
docs citations

53
times ranked

4288
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Status and Future Perspectives on mRNA Drug Manufacturing. <i>Molecular Pharmaceutics</i> , 2022, 19, 1047-1058.	2.3	44
2	Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12199.	5.5	14
3	Voices in Molecular Pharmaceutics: Meet Dr. Anna Blakney, an Engineer Who Seeks To Develop the Next Generation of Gene Therapies. <i>Molecular Pharmaceutics</i> , 2022, 19, 1231-1232.	2.3	0
4	Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach. <i>Molecular Pharmaceutics</i> , 2022, 19, 1892-1905.	2.3	30
5	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. <i>Journal of Controlled Release</i> , 2021, 330, 1250-1261.	4.8	28
6	An Update on Self-Amplifying mRNA Vaccine Development. <i>Vaccines</i> , 2021, 9, 97.	2.1	117
7	Next-generation COVID-19 vaccines: here come the proteins. <i>Lancet, The</i> , 2021, 397, 643-645.	6.3	9
8	Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. <i>Molecular Therapy</i> , 2021, 29, 1174-1185.	3.7	40
9	Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. <i>Npj Vaccines</i> , 2021, 6, 65.	2.9	36
10	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893.	5.8	104
11	Effect of tissue microenvironment on fibrous capsule formation to biomaterial-coated implants. <i>Biomaterials</i> , 2021, 273, 120806.	5.7	41
12	The next generation of RNA vaccines: self-amplifying RNA. <i>Biochemist</i> , 2021, 43, 14-17.	0.2	14
13	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. <i>Journal of Controlled Release</i> , 2021, 338, 201-210.	4.8	53
14	Neutrophils Enable Local and Noninvasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart. <i>Advanced Materials</i> , 2020, 32, e2003598.	11.1	66
15	An improved synthesis of poly(amidoamine)s for complexation with self-amplifying RNA and effective transfection. <i>Polymer Chemistry</i> , 2020, 11, 5861-5869.	1.9	8
16	Ornithine-derived oligomers and dendrimers for <i>in vitro</i> delivery of DNA and <i>ex vivo</i> transfection of skin cells via saRNA. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4940-4949.	2.9	15
17	Precisely targeted gene delivery in human skin using supramolecular cationic glycopolymers. <i>Polymer Chemistry</i> , 2020, 11, 3768-3774.	1.9	8
18	The <i>In Vitro</i> , <i>Ex Vivo</i> , and <i>In Vivo</i> Effect of Polymer Hydrophobicity on Charge-Reversible Vectors for Self-Amplifying RNA. <i>Biomacromolecules</i> , 2020, 21, 3242-3253.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. <i>Nature Communications</i> , 2020, 11, 3523.	5.8	357
20	Mannosylated Poly(ethylene imine) Copolymers Enhance saRNA Uptake and Expression in Human Skin Explants. <i>Biomacromolecules</i> , 2020, 21, 2482-2492.	2.6	30
21	Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. <i>ACS Nano</i> , 2020, 14, 5711-5727.	7.3	92
22	Geografiese ligging beïnvloed vaginale mikrobiële profiele in Suid-Afrikaanse vroue. <i>South African Journal of Science and Technology</i> , 2020, 38, 41-49.	0.1	1
23	Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. <i>Gene Therapy</i> , 2019, 26, 363-372.	2.3	137
24	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. <i>Journal of Controlled Release</i> , 2019, 304, 65-74.	4.8	30
25	The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants. <i>ACS Nano</i> , 2019, 13, 5920-5930.	7.3	44
26	One Size Does Not Fit All: The Effect of Chain Length and Charge Density of Poly(ethylene imine) Based Copolymers on Delivery of pDNA, mRNA, and RepRNA Polyplexes. <i>Biomacromolecules</i> , 2018, 19, 2870-2879.	2.6	51
27	Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females. <i>Infection and Immunity</i> , 2018, 86, .	1.0	136
28	Structural Components for Amplification of Positive and Negative Strand VEEV Splezicons. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 71.	1.6	31
29	In vitro–ex vivo correlations between a cell-laden hydrogel and mucosal tissue for screening composite delivery systems. <i>Drug Delivery</i> , 2017, 24, 582-590.	2.5	10
30	Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention. <i>Biomaterials</i> , 2017, 144, 1-16.	5.7	55
31	Application of electrospun fibers for female reproductive health. <i>Drug Delivery and Translational Research</i> , 2017, 7, 796-804.	3.0	19
32	Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC–MS/MS assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1025, 110-118.	1.2	11
33	Delayed BCG immunization does not alter antibody responses to EPI vaccines in HIV-exposed and -unexposed South African infants. <i>Vaccine</i> , 2016, 34, 3702-3709.	1.7	9
34	Rapidly Biodegrading PLGA-Polyurethane Fibers for Sustained Release of Physicochemically Diverse Drugs. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 1595-1607.	2.6	26
35	In pursuit of functional electrospun materials for clinical applications in humans. <i>Therapeutic Delivery</i> , 2016, 7, 387-409.	1.2	32
36	Reply to Thyssen et al. <i>Journal of Infectious Diseases</i> , 2015, 212, 1342-1343.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission. <i>Molecular Pharmaceutics</i> , 2015, 12, 4363-4374.	2.3	40
38	Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants. <i>Vaccine</i> , 2015, 33, 4782-4789.	1.7	10
39	Linking the foreign body response and protein adsorption to PEG-based hydrogels using proteomics. <i>Biomaterials</i> , 2015, 41, 26-36.	5.7	129
40	Immunomodulation by mesenchymal stem cells combats the foreign body response to cell-laden synthetic hydrogels. <i>Biomaterials</i> , 2015, 41, 79-88.	5.7	122
41	Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. <i>International Journal of Nanomedicine</i> , 2014, 9, 2967.	3.3	67
42	A Hydrogel Tissue Model for Evaluation of Triple-antiretroviral Electrospun Fibers as a Microbicide. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A156-A156.	0.5	0
43	Intramyocardial Injection of a Synthetic Hydrogel with Delivery of bFGF and IGF1 in a Rat Model of Ischemic Cardiomyopathy. <i>Biomacromolecules</i> , 2014, 15, 1-11.	2.6	41
44	Electrospun fibers for vaginal anti-HIV drug delivery. <i>Antiviral Research</i> , 2013, 100, S9-S16.	1.9	84
45	Understanding the host response to cell-laden poly(ethylene glycol)-based hydrogels. <i>Biomaterials</i> , 2013, 34, 952-964.	5.7	30
46	Student award winner in the undergraduate category for the society of biomaterials 9th World Biomaterials Congress, Chengdu, China, June 1-5, 2012. <i>Journal of Biomedical Materials Research - Part A</i> , 2012, 100A, 1375-1386.	2.1	367
47	Temporal progression of the host response to implanted poly(ethylene glycol)-based hydrogels. <i>Journal of Biomedical Materials Research - Part A</i> , 2011, 96A, 621-631.	2.1	70